Diffusion Weighted MR Imaging of Prostate Adenocarcinoma after Endocrinotherapy:Influence of B Value
CHEN Zhi-qiang,GUO Yu-lin,WANG Xiao-ying,LI Fei-yu,GUO Xue-mei,JIANG Xue-xiang
DOI: https://doi.org/10.3321/j.issn:1003-3289.2007.05.034
2007-01-01
Abstract:Objective To assess the changes of the apparent diffusion coefficient (ADC) values of the cancerous and noncancerous regions of prostate peripheral zone in patients confirmed with prostate cancer with endocrine therapy. Methods Diffusion-weighted echo-planar imaging (EPI) sequences with different b values were performed in 32 patients with evidence of prostate cancer, including 18 patients treated with endocrine therapy over 6 months and 14 nontreated matched patients as controls. The apparent diffusion coefficients (ADCs) were calculated from different diffusion-weighted imaging using different b values. According to the pathological results obtained by ultrasound guided systemic biopsy, the locations of the prostate cancerous region were marked as one or more of the sextants. Results Acceptable images for ADC measurement were obtained in all cases of different sequences. Compared with the mean ADC values in nontreated patients, mean values of endocrine treated patients increased in cancerous regions when b was 800,500 or 300 s/mm2 and decreased in noncancerous regions when b was 500 or 300 s/mm2 and didn't vary statistically with b value being 800 s/mm2. Under different b values, there was statistically difference of mean ADC values in the cancerous and noncancerous regions of prostate peripheral zone, bladder and the obturator internus between the treated and control patients. Conclusion The values of ADCs vary differently in cancerous and noncancerous regions. There was statistically difference of mean ADC values with different b values in the cancerous and noncancerous regions of prostate peripheral zone, bladder and the obturator internus between the treated and control patients. Measurement of ADCs might be useful to evaluate the efficacy of endocrine therapy for patients with prostate cancer.
What problem does this paper attempt to address?